Stifel Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $28
Benzinga Newsdesk 11 months ago
NewsPrice TargetInitiationAnalyst Ratings
Stifel analyst Paul Matteis initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $28.
Stifel analyst Paul Matteis initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $28.